SK Capital to invest in Swixx BioPharma at a €1.5bn valuation.

SK Capital, a New York-based private investment firm, agreed to invest in Swixx BioPharma, a provider of pharmaceutical commercialization services, at a €1.5bn valuation. "We are excited to partner with Swixx BioPharma, a company that shares our commitment to improving patient outcomes and advancing healthcare. Our investment underscores confidence in Swixx’s leadership and its ability to deliver sustainable business growth across diverse markets," Aaron Davenport, SK Capital Managing Director.